Study of CLN-978 for Sjögren's disease
Treatments studied
Part of Bones, joints & muscles, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that helps your immune system target and destroy disease-causing B cells. It's for people with moderate to severe Sjögren's disease who haven't had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Sjögren's disease for at least 6 months and have moderate to severe symptoms, like joint pain and swelling.
- Your blood tests need to show certain levels of immune cells (lymphocytes, neutrophils, B cells) and normal organ function (kidney, liver).
- You cannot have other autoimmune diseases, active infections (including COVID-19, hepatitis, HIV, or tuberculosis), or a history of serious nervous system problems.
- You must not have had a splenectomy (spleen removal) or received a live vaccine within the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called DDY391 for people with Sjögren's disease. The goal is to see if it can reduce symptoms and improve quality of life, and to check for side effects.
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that targets a protein on certain immune cells (B cells) to try to calm overactive immune activity in lupus. The goal is to see if it can reduce lupus symptoms for people whose disease has not been controlled by other treatments.
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
Hear when a new Sjögren trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.